Youke Yi (优可依)优可依
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 北京紫光制药有限公司Chinese legal name: 北京紫光制药有限公司
主要成分Active Ingredients
- 依西美坦Yixi Meitan
药物知识说明
依西美坦是一种在国家药监局注册认定的药品。该药品含有依西美坦-0d20e550等成分。
该药品关联的活性成分包括：依西美坦Yixi Meitan。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：北京紫光制药有限公司Chinese legal name: 北京紫光制药有限公司。
您可以探索含有相同成分的其他药品：依西美坦-0d20e550成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 优可依) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 依西美坦Yixi Meitan.
Manufacturers recorded for this product: 北京紫光制药有限公司Chinese legal name: 北京紫光制药有限公司.
Explore other medicines containing the same ingredient: 依西美坦 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 优可依Recorded Chinese name: 优可依
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 25mg25 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 北京紫光制药有限公司Chinese legal name: 北京紫光制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20020008
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20020008
Manufacturer
Chinese legal name: 北京紫光制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20020008
生产企业
北京紫光制药有限公司(国产)
适应症
本品适用于以他莫昔芬治疗后病情进展的绝经后晚期乳腺癌患者。
用法用量
一次一片（25mg），一日一次，饭后口服，轻度肝肾功能不全者不需要调节给药剂量.
不良反应
本品的主要不良反应有:恶心、口干、便秘、腹泻、头晕、失眠、皮疹、疲劳、发热、浮肿、疼痛、呕吐、腹痛、食欲增加、体重增加等。其次文献报道还有高血 压、抑郁、焦虑、呼吸困难、咳嗽。其他还有淋巴细胞计数下降、肝功能指标（如丙氨酸转移酶等）异常等。在临床试验中，只有3%的病人由于不良反应终止治 疗，主要在依西美坦治疗的前10周内，由于不良反应在后期终止治疗者不常见（0.3%）。
禁忌
对本品或本品内赋形剂过敏的患者禁用。
注意事项
1.绝经前的女性一般不用依西美坦片剂。依西美坦不可与雌激素类药物连用，以免出现干扰作用。
2.中，重度肝功能，肾功能不全者慎用。超量服用依西美坦可使其非致命性不良反应增加。
3.运动员慎用。
贮藏
遮光，密封保存。
规格
25mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.